Published in N Engl J Med on November 17, 2011
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) | NCT02141672
ACTHar in the Treatment of Lupus Nephritis (ACTHar) | NCT02226341
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) (2015) 1.54
Nephrology in china. Nat Rev Nephrol (2013) 1.38
Renal involvement in autoimmune connective tissue diseases. BMC Med (2013) 1.21
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol (2014) 1.18
Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun (2012) 1.15
Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis (2015) 1.14
Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther (2012) 1.14
Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis (2014) 1.11
Update on differences between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Res Ther (2013) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol (2012) 1.02
Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest (2013) 0.96
Diagnosis and treatment of lupus nephritis flares--an update. Nat Rev Nephrol (2012) 0.92
Lupus nephritis: an update. Clin Exp Nephrol (2015) 0.86
Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health (2012) 0.85
Latest advances in connective tissue disorders. Ther Adv Musculoskelet Dis (2013) 0.85
What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol (2015) 0.84
Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol (2016) 0.84
The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS One (2013) 0.83
Glomerular disease: perspectives on maintenance therapy in lupus nephritis. Nat Rev Nephrol (2012) 0.83
Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med (2015) 0.83
Connective tissue diseases: Management of lupus nephritis-new guidelines revealed. Nat Rev Rheumatol (2012) 0.83
Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther (2012) 0.82
A critical review of clinical trials in systemic lupus erythematosus. Lupus (2016) 0.81
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis. Clin J Am Soc Nephrol (2014) 0.81
Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One (2015) 0.81
[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z Rheumatol (2013) 0.80
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol (2013) 0.80
Lupus nephritis: Implications of the new ACR lupus nephritis guidelines. Nat Rev Nephrol (2012) 0.80
Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet (2015) 0.79
Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol (2016) 0.79
Toward better treatment for lupus nephritis. N Engl J Med (2011) 0.79
The treatment of systemic lupus proliferative nephritis. Pediatr Nephrol (2012) 0.79
Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clin Rheumatol (2014) 0.78
Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis. Springerplus (2014) 0.78
Fertility preservation in patients receiving cyclophosphamide therapy for renal disease. Pediatr Nephrol (2014) 0.78
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther (2015) 0.78
Recent clinical trials in lupus nephritis. Rheum Dis Clin North Am (2014) 0.78
Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging. Adv Chronic Kidney Dis (2013) 0.78
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. Rheumatol Int (2016) 0.78
A treatment algorithm for children with lupus nephritis to prevent developing renal failure. Int J Prev Med (2014) 0.77
Pediatric lupus nephritis: Management update. World J Nephrol (2014) 0.77
Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) (2014) 0.77
[Lupusnephritis]. Z Rheumatol (2012) 0.77
Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol (2014) 0.76
Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol (2016) 0.75
Connective tissue disease: Trial of SLE therapies in real-world settings. Nat Rev Rheumatol (2012) 0.75
Comparative Rates of Serious Infections among Patients with Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. Arthritis Rheumatol (2016) 0.75
Dialogue: Early predictors of long-term lupus nephritis outcomes: looking into the future. Lupus Sci Med (2015) 0.75
Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study. BMC Nephrol (2016) 0.75
Mycophenolate or azathioprine maintenance in lupus nephritis. N Engl J Med (2012) 0.75
Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis. Int J Nephrol (2015) 0.75
A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience. Lupus Sci Med (2016) 0.75
Meryl Streep and the problems of clinical trials. Arthritis Res Ther (2012) 0.75
Lupus nephritis: Transatlantic management recommendations compared. Nat Rev Rheumatol (2012) 0.75
Lupus nephritis: MAINTAINing perspective in lupus nephritis trials. Nat Rev Nephrol (2015) 0.75
Lupus nephritis in children - 10 years' experience. Cent Eur J Immunol (2016) 0.75
The contribution of the programmed cell death machinery in innate immune cells to lupus nephritis. Clin Immunol (2016) 0.75
Glomerular necrotic lesions and long-term outcomes among patients with proliferative lupus nephritis. Int J Clin Exp Pathol (2015) 0.75
Lupus Nephritis: A Different Disease in European Patients? Kidney Dis (Basel) (2015) 0.75
Mycophenolate or azathioprine maintenance in lupus nephritis. N Engl J Med (2012) 0.75
Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol (2016) 0.75
Current and emerging treatment options in the management of lupus. Immunotargets Ther (2016) 0.75
Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol (2017) 0.75
Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol (2017) 0.75
Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study. Clin Rheumatol (2014) 0.75
[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]. Z Rheumatol (2017) 0.75
Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. Clin Rheumatol (2015) 0.75
[Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs]. Z Rheumatol (2013) 0.75
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA (2009) 8.56
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol (2009) 5.02
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med (2005) 3.49
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol (2010) 2.92
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int (2003) 2.47
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int (2004) 2.39
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2007) 2.38
ANCA-associated glomerulonephritis in the very elderly. Kidney Int (2010) 2.36
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.33
A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int (2010) 2.22
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis (2010) 2.21
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis (2011) 2.11
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol (2008) 2.08
Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol (2004) 1.99
Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum (2007) 1.98
Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol (2004) 1.94
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis (2011) 1.88
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) (2010) 1.88
Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol (2007) 1.87
Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis (2009) 1.86
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum (2007) 1.83
Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis (2010) 1.81
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest (2002) 1.81
Membranoproliferative glomerulonephritis. Pediatr Nephrol (2009) 1.80
Collapsing glomerulopathy. Semin Nephrol (2003) 1.80
Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol (2005) 1.80
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79
A quality indicator set for systemic lupus erythematosus. Arthritis Rheum (2009) 1.77
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol (2007) 1.74
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2002) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol (2009) 1.67
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol (2011) 1.67
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens (2009) 1.66
Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol (2006) 1.64
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol (2012) 1.58
Glomerular disease: why is there a dearth of high quality clinical trials? Kidney Int (2010) 1.53
Immune complex formation in IgA nephropathy: a case of the 'right' antibodies in the 'wrong' place at the 'wrong' time? Nephrol Dial Transplant (2009) 1.53
Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun (2006) 1.51
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant (2003) 1.50
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) (2009) 1.50
Relationship of left ventricular hypertrophy and diastolic function with cardiovascular and renal outcomes in African Americans with hypertensive chronic kidney disease. Hypertension (2013) 1.49
Updates on the treatment of lupus nephritis. J Am Soc Nephrol (2010) 1.48
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) (2009) 1.48
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Risk factors for ANA positivity in healthy persons. Arthritis Res Ther (2011) 1.45
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) (2010) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract (2005) 1.44
Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol (2012) 1.43
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med (2002) 1.43
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis (2013) 1.41
Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis. Nephrol Dial Transplant (2012) 1.41
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.39
Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al. Arthritis Rheum (2006) 1.39
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A (2006) 1.38
Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol (2008) 1.38
Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol (2006) 1.38
A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol (2004) 1.37
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol (2005) 1.37